SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)

Table 4 Prevention of amyloid accumulation and microglial activation by SAR255952 and its human homolog SAR228810 in immunotolerized and non-immunotolerized APPSL transgenic mice

	Treatment groups	No. of animals	Mean value	± SEM	Effect size	p value
Amyloid β immunohistochemistry total area cortex (μm²)
Non-immunotolerized	Ctrl-IgG1	8	696,471	81,813
Immunotolerized	Ctrl-IgG1	9	569,092	63,738	−18% vs non-immunotolerized	NS
Immunotolerized	SAR228810	8	207,996	27,252	−63% vs immunotolerized DM4	< 0.001
Immunotolerized	SAR255952	8	197,600	17,064	−65% vs immunotolerized DM4	< 0.001
Cystatin F mRNA hippocampus (related units)
Non-immunotolerized	Ctrl-IgG1	12	78	7.5
Immunotolerized	Ctrl-IgG1	12	80	8.9	+ 3% vs non-immunotolerized	NS
Immunotolerized	SAR228810	12	24	3.2	−70% vs immunotolerized DM4	< 0.001
Immunotolerized	SAR255952	9	28	2.8	−66% vs immunotolerized DM4	< 0.001

All animals were treated with the same dose (10 mg/kg) of the indicated antibodies
NS not significant, SEM standard error of the mean

ISSN: 1758-9193